-
Market Insight: ECO 2026 Highlights Orforglipron's Potential to Reshape the $100B Oral GLP-1 Market
May , 19 2026
The European Congress on Obesity (ECO 2026) has concluded, but the excitement surrounding Orforglipron (LY3502970) continues to reverberate throughout the global pharmaceutical industry. For millions ...
read more
-
Orforglipron vs. Semaglutide vs. Tirzepatide: The Ultimate 2026 Weight Loss Drug Comparison
May , 21 2026
1. Introduction: The GLP-1 Evolution The weight loss pharmaceutical market has dramatically shifted with the 2026 FDA approval of Orforglipron (Foundayo). This new oral, non-peptide agonist challenges...
read more